SR One

Activity in this selectionj-p-morgan-life-sciences-private-capital-2d7805a5

By stage

Series A3

Series B2

Biotech4

Healthtech1

United States4

United Kingdom1

5 in this selection

Jul 22

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B

Role not disclosed

Jul 14

Developing transformative, best-in-class neuropsychiatric therapies

$65MSeries B

Role not disclosed

Mar 3

Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions

$45MSeries A+

Role not disclosed

Jan 9

Develops therapeutics for pulmonary diseases, specifically COPD

$200MSeries A

Role not disclosed

Jan 7

Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions

$50MSeries A

Role not disclosed